|
 |
|
|
|
|
|
|
|
 |
|
 |
|
|
|
Investments -
Life Sciences
|
 |
|
Committed to Quality of Life
With an aging world population, a rising interest in personal health management, increased amounts of disposable income, and the access to up-to-date information afforded by the Internet – life extension and quality of life improvement are primary motivators in the Life Sciences market, and the driving force behind GlenRock's Life Sciences investment strategy.
Investing in Tomorrow's Pioneers
With the right combination of a highly-developed medical community, world-class scientific resources, and excellent technological capabilities, Israel has produced numerous commercial Life Sciences success stories. GlenRock identifies and invests in cutting-edge Israeli Life Sciences technology at all stages of commercialization – from ideas on paper to viable companies breaking new ground in the fields of medical devices and biotechnology.
GlenRock's well-rounded Life Sciences portfolio includes:
|
 |
|
 |
 |
Kamada (TASE:KMDA) is a biopharmaceutical company engaged in development, production and marketing of specialty plasma therapeutics, specific and general immune globulins and other prescribed medicines using sophisticated chromatographic purification technology.
Kamada is producing more than 10 different pharmaceuticals primarily for critical care situations that arise in emergency rooms, operating theaters and intensive care units.
The products are licensed and marketed in the local market and in 15 other countries across the globe.
Latest News: The company received an FDA approval for its lead product the Glassia - a new liquid, ready- to-use treatment for Alpha-1 Antitrypsin Deficiency. In addition the company received an EMEA clearance to enter phase 2/3 in its inhaled product. The Aerosolized AAT was also granted a new orphan drug designation for the treatment of Bronchiectasis for which the company completed phase 2 trial. Furthermore, the company reported successful completion of phase 2 trial in Cystic Fibrosis patients with its Aerosolized AAT. During 2010 The company received an FDA approval to enter into a fast track Phase III in the KamRab product - An anti-rabies immune globulin.
http://www.kamada.com
|
|
|
|
|
 |
|
Evogene (TASE:EVGN) is an agro-biotechnology company specializing in the development of superior crops through genome remodeling. Evogene's solutions are based on the tight integration of patented technologies and expertise in computational genomics, functional genomics and advanced high throughput plant breeding. Evogene's core technology platform mimics and accelerates evolutionary processes and can address concerns associated with transgenic plants.
Latest News: The company announced a strategic collaboration with Monsanto (NYSE: MON) one of the worldwide leading seed companies. Additional collaborations were established with Bayer CropScience, DuPont, Biogemma and other leading companies. During 2010 the company established a cooperation with NASA in the field of Biofuel.
http://www.evogene.com
|
|
|
|
|
 |
|
Rosetta Genomics (NasdaqGM: ROSG) is an integrative genomics company which has recently discovered a large number of novel genes related to many major diseases, using a radically novel bioinformatic approach. Rosetta Genomics licenses use of the company's numerous patent-pending disease-related genes to drug and diagnostic developers and manufacturers, who develop next-generation gene-based therapeutics and diagnostics based upon these genes.
Latest News: During 2007 the company completed a successful IPO on NASDAQ
The company entered into an exclusive U.S. licensing and distribution agreement with Prometheus Laboratories for its first three cancer diagnostic tests.
http://www.rosettagenomics.com
|
|
|
|
|
 |
|
Vascular Biogenics (VBL) is a biopharmaceutical company dedicated to the development of innovative therapies targeting the vascular wall. Based on more than 10 years of academic research in one of the leading medical centers in Israel, VBL's products introduce novel approaches to the fight against cancer and cardiovascular diseases. VBL's vision is to develop safe and simple solutions based on understanding and mimicking natural processes occurring within the vascular wall.
Latest News: The company's compound for the treatment of patients with psoriasis is currently in Phase 2. The company is also entering in 2010 Phase 2 clinical development with its lead oncology drug candidate, which successfully completed a Phase 1/2 trial in patients with cancer.
http://www.vbl.co.il
|
|
|
|
|
 |
|
LifeBond is a medical device company engaged in the development of active hemostatic solutions to minimize fatalities and damage from trauma wounds and surgical injuries. LifeBond will further develop its core technology into a range of products with the goal to establish a leading position in emerging bio-surgical market niches.
Latest News: During 2010 a First In Man Study was launched.
|
|
|
|
|
 |
|
BrainsGate develops a novel technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.
Latest News: The company is conducting clinical trials in India, Germany, Israel and Hungary.
http://www.brainsgate.com/
|
|
|
|
|
 |
|
Valtech Cardio is developing Percutaneous Annuloplasty ring valve repair for the treatment of Mitral Valve Regurgitation. Using a simple catheterization process for implementing the device which treats Mitral Valve Regurgitation, Valtech's treatment will be an alternative to the invasive open heart procedures that are currently in use today.
http://www.valtechcardio.com
|
|
|
|
|
 |
|
NESS utilized the technology of surface neuromuscular electrical stimulation to develop solutions for activating paralyzed muscles. Its first product is the Handmaster - a non-invasive system for paralyzed hands. NESS is developing innovative rehabilitation products that focus on altered movement or paralysis due to disorders and trauma of the central nervous system, or due to orthopedic disorders. The NESS systems are designed for home use and provide the potential for both therapeutic benefits and enhanced function by means of surface neuromuscular electrical stimulation.
Latest News: During 2007 the company was sold to Bioness.
http://www.nessltd.com/
|
|
|
|
|
 |
|
Bioness offers award-winning medical devices designed to benefit people with stroke, Multiple Sclerosis, traumatic brain injury, Cerebral Palsy, and spinal cord injury. These products use electrical stimulation to help people regain mobility and independence, to improve quality of life and productivity.
Latest News: The company is to distribute new products for neurologically impaired patients.
http://www.bionessinc.com/
|
|
|
|
|
 |
|
Roei Medical Technologies develops innovative technology (FDA and CE approved) that improves the accuracy, efficacy, and safety of endoscopic urological procedures. The Roei resectoscope uses a unique scooping motion to provide surgeons the flexibility of approaching a tumor or tissue from a different angle, which translates the axial maneuver at the handgrip into a rotational side-to-side, bidirectional movement at the distal cutting edge.
Latest News: The company's products were approved for marketing by the FDA and the CE.
http://www.roeimedical.com/
|
|
|
|
|
 |
|
Power Paper is a leading provider of micro-power source technology, which addresses a growing trend across a wide range of industries towards ultra-thin and flexible micro-powered devices. Power Paper's patented thin and flexible energy cells can be adapted to fit the size, thickness and form factors required for the design of any product. These environment-friendly, safe batteries require no metal casing, and can be printed cost-effectively directly onto paper, plastics or other surfaces by standard printing equipment. Based on Power Paper's thin and flexible power source and printable electronics technologies, the company's non-invasive, active delivery patch is a robust platform that can be employed in multiple therapeutic areas. The company's next-generation active patches have been proven in clinical trials to provide quicker results and long-lasting healing benefits.
http://www.powerpaper.com
|
|
|
|
|
 |
|
Visionsense is positioning itself as a high-end technology company, aiming to drive the Minimally Invasive Surgery ("MIS") visualization market from 2-Dimensional optics to "smart" 3-Dimensional sensors.
http://www.visionsense.com
|
|
|
|
|
Yossi Gross
Bio Sciences |
|
Yossi Gross is a serial entrepreneur in the field of advanced technologies for medical devices.
Yossi has established 15 companies thus far, in most of which GlenRock has invested, including:
- BioControl - New generation of active implantable devices affecting the behavior of muscles and nerves of the autonomic nervous system. The company sold its urology business for $90M to American Medical Systems.
- BrainsGate - Unique neuro-stimulation treatment for stroke.
- DuoCure - Innovative intraluminal minimally invasive implantable device for treatment of obesity.
- E-Pill Pharma - Develops an “electrical pill” performing electrical nerve stimulation of the intestines (ENSI). ENSI affects the absorption properties of the GI tract membrane.
- Beta-Stim - Minimally invasive implantable neuro-stimulator to treat obesity and type II diabetic patients.
- Beta-O2 - Artificial pancreas which contains insulin producing Beta cells.
|
|
|
|
 |
|
Rainbow Medical -
A private investment company founded by the serial entrepreneur Yossi Gross, GlenRock Israel and managed by Efi Cohen-Arazi, which aims to seed and grow companies, mostly invented by the serial entrepreneur Yossi Gross, that develop breakthrough medical device-based therapeutic platforms addressing significant unmet market need and leads them to becoming high value companies. Rainbow Medical is committed to generating significant returns from its portfolio of cutting edge medical device technologies in a diverse range of medical fields. Collaboration was established with OXO Capital, a US based team of seasoned medical device professionals, founded and led by Larry Best, with a track record of successful execution in the medical device space. The OXO team provides access to an extensive network of industry relationships and contacts, experience based strategic guidance and insight as well as a geographic US presence
Latest News: Maxillent is launching a second clinical site. Glusense, Enopace, Slender, Fibro Control, Vascular Dynamics, and Pharmalight are to initiate First in Man clinical studies throughout 2010
http://www.rainbowmedical.co.il/
|
|
|
 |
|
 |
|
|
|
